Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.
Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55%
Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III LUCIDITY trial of avexitide met its primary endpoint, reducing the composite rate of clinically significant hypoglycemic events by 55% versus placebo in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery.
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild
Amylyx Pharmaceuticals (AMLX) is transitioning from its ALS legacy to a late-stage endocrine company, with avexitide as its lead asset. AMLX's $250.8M cash runway extends into 2028, supporting LUCIDITY Phase 3 readout, regulatory submission, and potential 2027 launch without near-term financing risk. LUCIDITY's pivotal trial targets post-bariatric hypoglycemia, a large orphan market with no approved therapies; topline results expected late August or early September 2026.
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call Transcript
Amylyx Pharmaceuticals Q2 Earnings Call Highlights
Amylyx Pharmaceuticals NASDAQ: AMLX said its pivotal Phase III LUCIDITY trial of avexitide in post-bariatric hypoglycemia, or PBH, has completed final patient visits, with top-line data expected in late August or early September.
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus
Amylyx Pharmaceuticals NASDAQ: AMLX is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the third quarter, Co-Chief Executive Officer Joshua Cohen said at the BofA Annual Healthcare Conference.
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC
Ally Bridge Group NY LLC acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 437,391 shares of the company's stock, valued at approximately $5,944,000. Amylyx Pharmaceuticals makes up approximately 3.6%
Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by Alpha Wave Global LP
Alpha Wave Global LP increased its position in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) by 18.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 327,312 shares of the company's stock after acquiring an additional 51,470 shares during the period. Amylyx Pharmaceuticals
